BURLINGTON, Mass., Sept. 17 /PRNewswire/ — InfraReDx,
Inc., a medical device company developing intelligent
cardiovascular diagnostic imaging technologies, today announced
that its new LipiScan™ IVUS Coronary Imaging System will be
highlighted during the annual Transcatheter Cardiovascular
Therapeutics meeting (TCT 2010). The novel
device, which was recently cleared by the U.S. Food and Drug
Administration (FDA), will be featured in scientific and clinical
symposia, live case broadcasts, product demonstrations and poster
abstract sessions. TCT 2010 is being held September 21-25, 2010 at
the Walter E. Washington Convention Center (“the convention
center”) in Washington, D.C. TCT is the world’s largest educational
meeting specializing in interventional cardiovascular medicine and
showcasing the latest advances in techniques, therapies and
clinical research.
The Company expects to conduct a broad commercial launch of the
system within the U.S. by year-end 2010, and anticipates regulatory
approval and launch in Europe during 2011.
The LipiScan IVUS system utilizes a novel multimodality imaging
catheter; the first ever to combine the complementary technologies
of near-infrared (NIR) spectroscopy and intravascular ultrasound
(IVUS). This combination enables interventional cardiologists to
rapidly determine both the structure of plaque (via IVUS) along
with its chemical composition (via NIR spectroscopy). NIR
spectroscopy is the only technology cleared by the FDA for the
specific task of detection of lipid-core coronary plaques (LCP).
Such plaques can adversely impact the safety of stenting and are
associated with heart attacks that occur in those who have received
stents and in the general population.
Dr. James Muller, founder and chief executive officer of
InfraReDx, Inc. noted that the “LipiScan IVUS system is the
culmination of a major effort to develop
‘/>”/>
SOURCE
